Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib

Publisher： Karger

E-ISSN： 1423-0232|79|5-6|355-362

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.5-6, 2011-03, pp. : 355-362

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Correlation of C-Reactive Protein with Survival and Radiographic Response to First-Line Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 665-670

Karger

Access to resources Recommend Favorite

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

By  

Oncology, Vol. 79, Iss. 5-6, 2011-04 ,pp. : 423-429

Karger

Access to resources Recommend Favorite

Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice

By  

Oncology, Vol. 84, Iss. 5, 2013-02 ,pp. : 255-264

Karger

Access to resources Recommend Favorite

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 83, Iss. 5, 2012-09 ,pp. : 248-256

Karger

Access to resources Recommend Favorite

Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras

By  

Oncology, Vol. 76, Iss. 4, 2009-02 ,pp. : 239-246

Karger

Access to resources Recommend Favorite